USD10
ADCT Shares
About ADC TherapeuticsADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
USD10
ADCT Shares
About ADC TherapeuticsADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 24 at 1:30 PM GMT+0
MARKET CAP
$483.12M
OPEN PRICE
$3.97
LOW (1Y)
$1.05
HIGH (1Y)
$4.80
LOW (24H)
$3.87
HIGH (24H)
$4.00
VOLUME (24H)
$354.28K
46.55%
Price history
Time | Price | Change |
|---|---|---|
Today | $3.97 | |
1 Day | $4.08 | |
1 Week | $4.20 | |
1 Month | $4.39 | |
1 Year | $1.62 |
Discover more
Legal
All securities and investments are offered by Coinbase Capital Markets Corp, member FINRA/SIPC. Securities services offered by Coinbase Capital Markets Corp are separate from digital asset services provided by Coinbase Inc., and any affiliates or crypto asset services provided under MiCA by Coinbase Luxembourg S.A. SIPC does not apply to digital assets or cash held in your Coinbase Inc. account. Additional information about your broker, Coinbase Capital Markets Corp, can be found on FINRA’s BrokerCheck. Execution, clearing and custody of all securities are provided by Apex Clearing Corporation.This page and the content herein is for informational purposes only and does not constitute the provision of investment advice. The customer assumes full responsibility for its trading activity and should consult its advisors for its specific situation. This material is not (i) an offer, or solicitation of an offer, to invest in, or to buy or sell, any interests or shares, or to participate in any investment or trading strategy, (ii) intended to provide accounting, legal, or tax advice, or investment recommendations. The information is believed to be current as of the date indicated and may not be updated or otherwise revised to reflect information that subsequently became available or a change in circumstances after the date of publication. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. Recipients should consult their advisors before making any investment decision.All ticker names are trademarks of their respective holders. Any ticker reference does not imply any affiliation with or endorsement by a third party. Real-time quote and/or trade prices are not sourced from all markets, source: Nasdaq Last Sale. Morningstar data ©2026.
